Variations Requiring Assessment (Veterinary Medicines) - Q&A Update

The EMA updates its procedural Q&A for veterinary medicines, adding Question 23 regarding variations requiring assessment.

Source updated: Jul 3, 2026

Primary source: Guidance to applicants / marketing authorisation holders on oral explanations at CVMP

PV Impact Brief

Urgency: HighConfidence: high

What changed

Addition of Question 23 to the procedural Q&A regarding variations for veterinary products.

Why it matters

This update enables MAHs to better navigate the requirements for submitting variations, streamlining the process for regulatory compliance in handling veterinary medicinal products.

Action needed

MAHs are advised to incorporate the updated FAQs into their compliance workflows and ensure that their submissions adhere to the updated guidance.

Relevant for: Regulatory Intelligence LeadQPPV
Processes impacted: Country Compliance
Owner: Regulatory Intelligence Lead
Review cadence: Review whenever updates to EMA guidance are published.

Policy change details

Document type: Q&A
Policy status: revised
Publication date: 2026-07-03
Policy change: The EMA has updated its Q&A on variations requiring assessment for veterinary medicines by adding Question 23.

Key changes

Addition of Question 23 to the procedural Q&A regarding variations for veterinary products.

Affected workflows

Country Compliance

Responsible groups

Regulatory AffairsPharmacovigilance

PV impact

Minor procedural update for veterinary MAH regulatory teams handling variations.

View regulator source

Source document details

Exact policy details

Submission of variations: Centrally authorised veterinary medicines require assessment under Regulation (EU) 2019/6.
Applies to: Applies to all marketing authorisation holders submitting variations for centrally authorised veterinary medicines.
This page provides guidance on how to apply for a variation on centrally authorised veterinary medicines requiring assessment under the Veterinary Medicinal Products Regulation. · p. 1 · High · Source
Electronic submission: Mandatory submission via the EMA e-Submission Gateway or Syncplicity Web Client.
Applies to: All submissions to the EMA related to applications for central marketing authorisation.
Electronic submission via the EMA e-Submission Gateway or Syncplicity Web Client is mandatory. · p. 1 · High · Source
Worksharing procedures: Complete dossier must be submitted via Gateway/Syncplicity Web Client for each centrally authorised product.
Applies to: Applies to worksharing procedures for centrally authorized products and nationally authorized products.
For worksharing procedures, the complete dossier should be submitted via the Gateway/Syncplicity Web Client for each centrally authorised product included in the worksharing procedure. · p. 2 · High · Source

Extracted documents

Variations requiring assessment (veterinary medicines) | European Medicines Agency (EMA)htmlhtml · high · 1 page
QRD Form 2 and checklist for the submission of day +25 files - veterinarydocxdocx · high · 1 page
Dossier requirements for submission of marketing authorisation and maximum residue limit (MRL) applications to the European Medicines Agency (EMA) and to members of the Committee for Medicinal Products for Veterinary use (CVMP)pdfpdf_text · high · 5 pages
Guidance to applicants / marketing authorisation holders on oral explanations at CVMPpdfpdf_text · high · 3 pages

Evidence and confidence

Confidence: highSource updated: Jul 3, 2026

Guidance to applicants / marketing authorisation holders on oral explanations at CVMP →Updated September 21, 2023
Dossier requirements for submission of marketing authorisation and maximum residue limit (MRL) applications to the Europ →Updated September 21, 2023
QRD Form 2 and checklist for the submission of day +25 files - veterinary →Updated November 4, 2025
European Medicines Agency →Updated July 3, 2026

Full briefing

Practical implication

MAHs are advised to incorporate the updated FAQs into their compliance workflows and ensure that their submissions adhere to the updated guidance.

The European Medicines Agency (EMA) has added Question 23 to its Q&A on variations requiring assessment (VRA) for veterinary medicines, involving a minor procedural update for marketing authorisation holders (MAHs) handling such variations.

What changed: Addition of Question 23 to the procedural Q&A regarding variations for veterinary products.

Why it matters: This update enables MAHs to better navigate the requirements for submitting variations, streamlining the process for regulatory compliance in handling veterinary medicinal products.

Practical implication: MAHs are advised to incorporate the updated FAQs into their compliance workflows and ensure that their submissions adhere to the updated guidance.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Veterinary Medicines #Variations #Q&A #Revised #European Medicines Agency #guidance #policy-change #firecrawl-policy-agent

Related updates for your role

publicMedicines and Healthcare products Regulatory Agency (MHRA) · United Kingdom · Updated May 23, 2026

MHRA confirms UK clinical trial safety reporting guidance is effective

Urgency: High

Safety lead to: (1) perform a UK-clinical-trial safety reporting gap assessment against MHRA’s effective guidance sections (MedDRA coding; AE/SAE; RSI governance; SUSARs; annual safety reporting; USMs; serious breaches; temporary suspension), (2) update controlled SOPs/WIs and training records to reflect “effective” status as of 28 Apr 2026, and (3) document deviations/gaps and open CAPA where needed for ongoing UK trials and new submissions.

ICSRCountry ComplianceRegulatory Intelligence Lead

SOP Impact4 SOPs

ConfidenceHigh

Relevant for: Regulatory Intelligence Lead, QPPV

verifiedRegulatory action: Guidance

Read impact briefarrow_forward

publicEuropean Medicines Agency · EU · Updated Jul 15, 2026

Reflection paper on particulars for safety signals for (traditional) herbal medicinal products

Urgency: High

Implement increased documentation and reporting processes for traditional herbal medicinal products. Ensure staff receive training on the complexities involved in signal management for these products.

Signal ManagementRegulatory Intelligence Lead

SOP Impact1 SOPs

ConfidenceHigh

Relevant for: Regulatory Intelligence Lead, Signal Management Lead

verifiedRegulatory action: Draft Guidance

Read impact briefarrow_forward

publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead

SOP Impact1 SOPs

ConfidenceHigh

Relevant for: Regulatory Intelligence Lead, PV Quality Lead

verifiedRegulatory action: Checklist

Read impact briefarrow_forward

publicEuropean Medicines Agency · EU · Updated Jul 15, 2026